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Simple Summary: Colorectal cancer that has become metastatic continues to have a poor outlook.
Many patients will undergo intensive chemotherapy, often with limited effects but many side effects.
In other types of cancer, immunotherapy has shown to be effective by targeting the immune cells
of the patient and restoring their function to fight off cancer. This review explores the up-to-date
evidence for immunotherapy in metastatic colorectal cancer. We have discussed in which patients
this treatment is effective, but also why this has not been effective in a large number of patients. By
summarizing the key components of the immune cells within the proximity to the tumour and its
areas of spread, we discuss how these components can be targeted. Areas of future research are also
highlighted, which includes combining immunotherapy with current treatments, such as surgery,
radiotherapy and chemotherapy as well as some recent advances from basic and translational studies
that promises to improve outcomes in these patients.
Abstract: Metastatic colorectal cancer carries poor prognosis, and current therapeutic regimes convey
limited improvements in survival and high rates of detrimental side effects in patients that may not
stand to benefit. Immunotherapy has revolutionised cancer treatment by restoring antitumoural
mechanisms. However, the efficacy in metastatic colorectal cancer, is limited. A literature search
was performed using Pubmed (Medline), Web of Knowledge, and Embase. Search terms included
combinations of immunotherapy and metastatic colorectal cancer, primarily focusing on clinical
trials in humans. Analysis of these studies included status of MMR/MSS, presence of combination
strategies, and disease control rate and median overall survival. Evidence shows that immune
checkpoint inhibitors, such as anti-PD1 and anti-PD-L1, show efficacy in less than 10% of patients
with microsatellite stable, MMR proficient colorectal cancer. In the small subset of patients with
microsatellite unstable, MMR deficient cancers, response rates were 40–50%. Combination strategies
with immunotherapy are under investigation but have not yet restored antitumoural mechanisms
to permit durable disease regression. Immunotherapy provides the potential to offer additional
strategies to established chemotherapeutic regimes in metastatic colorectal cancer. Further research
needs to establish which adjuncts to immune checkpoint inhibition can unpick resistance, and better
predict which patients are likely to respond to individualised therapies to not just improve response
rates but to temper unwarranted side effects.
Keywords: colorectal cancer; immunotherapy; metastases; immune checkpoint inhibitors; anti-PD1;
tumour microenvironment; targeted therapy; microsatellite instability; mismatch repair; tumour-
associated macrophages
1. Introduction
Colorectal cancer (CRC) is the second greatest cancer threat to life in the Western
World [1]. Very few advances have been made in targeting metastatic colorectal cancer
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(mCRC) effectively. CALGB/SWOG 80405 [2], Fire-3 [3] and PEAK [4] randomised con-
trolled trials have all firmly established bevacizumab (VEGFR-inhibitor), cetuximab and
panitumumab, (EGFR inhibitors) as first-line therapies in addition to FOLFOX/FOLFOXIRI
in the management of patients with metastatic colorectal cancer. However, the margins
of benefit in addition to standard therapies are minimal, with progression-free survival
in FIRE-3 enhanced from 5.8 months to 9.7 months with the addition of cetuximab in the
truly RAS wild-type patients [4]. These responses are in contrast to those seen in other
malignancies, such as melanoma, where in BRAF mutant cancer a combination of BRAF
and MEK inhibition with immunotherapy has revolutionised treatment and led to survival
for patients extending to a median of 2 years, from less than 9 months [5].
However, hope exists for patients with colorectal cancer that targeted therapies can
start to be applied to specific subgroups of patients. The recently coordinated BEACON
study on the failure of BRAF directed inhibition alone in BRAFV600E mutant patients
sought to address the role of EGRF pathway reactivation in resistance to therapy. Using a
combination of standard chemotherapy, encorafenib (BRAF inhibitor) and MEK inhibitor,
binimetinib, significantly improved survival in this dismal prognosis disease [6]. It is
important to recognise this only applies to 10% of patients with colorectal cancer, and in
late-stage disease, outcomes remain <10 months even with targeted therapy.
Despite these recent advances, surgery provides the potential for cure in patients with
metastatic disease. However, sadly most patients are not candidates for resection due to
the burden or distribution of disease. Colorectal cancer oncological therapies must look to
capitalise on the successes achieved in other cancers with immunotherapies to enhance
patient survival, combining these in the future where possible with surgical resection to
benefit patients with lower volume oligometastatic disease. An opportunity exists to bring
forward treatments that are being used in the most advanced disease to provide opportuni-
ties to achieve long-term survival in more patients with borderline resectable/resectable
metastatic disease. This review will focus on the mutational and transcriptomic landscape
of colorectal cancer and current understanding of drug positioning in disease subtypes.
We will illustrate previous and current trials of immune oncological agents in mCRC and
explore avenues for combinatorial immune oncological approaches in this disease.
2. Colorectal Cancer—Personalised Medicine for a Heterogeneous Disease
Patients presenting with colorectal cancer can be classified by stage of disease. Patients
are increasingly presenting early through screening with pre-cancerous polyps or localised
disease (stages 0–III). However, there are still a significant proportion of patients that
present with stage IV disease, which is frequently metastatic and not surgically operable.
Whilst local excision, major colorectal resection and metastasectomy have an important
role to play, it is the patients with metastatic colorectal cancer (mCRC) in whom systemic
therapeutic strategies offer poor response rates and limited potential for disease control.
Increasing understanding of major genotypic and phenotypic variation in colorectal cancer
permits a tailored strategy to help predict likely responses to a given agent, which max-
imises the benefit whilst minimising the suffering from side effects and toxicity in patients
who do not stand to benefit.
The most common mutations that are observed in colorectal tumours include APC
(40%), TP53 (65%), KRAS (50%) and SMAD4 (12%), amongst many others [7,8]. The major-
ity of colorectal cancers occur via the adenoma–carcinoma sequence, with an accumulation
of mutations occurring over time [9]. Until recently, chemotherapy for metastatic colorec-
tal cancer has included a combination of oxaliplatin, irinotecan, fluorouracil (5-FU) and
capecitabine, such as FOXFOX, FOLFIRI, FOLFIRINOX and CAPOX [10]. It is on the basis
of certain mutations in which targeted therapy has begun to be explored in the treatment
of colorectal cancer.
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2.1. Classification by Mutational Status of CRC
B-type RAF (BRAF) mutations occur in 5–15% of mCRC and are associated with right-
sided colon cancer [11]. Patients who have BRAF-mutant mCRC (V600E being the most
common mutation) are generally treated with FOLFOXIRI plus bevacizumab (monoclonal
antibody against VEGF-A) [10]. There is some controversy over the effectiveness of anti-
EGR therapies in patients with wild-type RAS but BRAF mutant tumours. A meta-analysis
by Rowland et al. concluded that the BRAF mutation status did not significantly affect
treatment benefit and that there was insufficient data to exclude patients with BRAF
mutations from anti-EGFR therapy [12]. This was in contrast to Pietrantonio et al., who
concluded that anti-EGFR therapy did not have any benefit beyond standard therapy in
patients with RAS wild-type, BRAF mutant colorectal cancer [13]. More recently, the VOLFI
study confirmed that the addition of panitumumab to mFOLFOXIRI in patients with RAS
wild-type metastatic CRC improved the ORR and indeed the rate of secondary resection
for metastases [14]. RAS mutations occur in approximately half of patients with colorectal
cancer and also affect the RAS-RAF-ERK signalling pathway [15]. Patients with RAS
activating mutations also have poorer prognosis and, such as BRAF, are predicted to have
resistance to anti-EGFR therapies, such as cetuximab and panitumumab [16]. Assessing the
mutation status of patients for BRAF and RAS mutant tumours allows targeted strategies to
maximise effectiveness and minimise toxicity. In patients who do not respond to anti-EGFR
therapy, MEK inhibitors are under investigation to target downstream effector pathways
(RAS-RAF-MEK-MAPK) to limit proliferation and promote tumoural apoptosis to inhibit
tumour growth [17]. It is of note that one trial is underway studying the role of cetuximab
and pembrolizumab in RAS-wild-type patients with colorectal cancer [18].
Mismatch repair (MMR) deficiency occurs through mutations or promoter hyperme-
thylation in MLH1, MSH2, MSH6 or PMS2 [19]. Due to a failure of these genes to repair
base–base mismatches during DNA replication, decreased genomic stability and progres-
sion to colorectal cancer occurs. As a result of this defect, large mutations at microsatellite
sequences are observed, termed microsatellite instability (MSI). Colorectal cancer speci-
mens undergo immunohistochemistry (IHC) as standard to assess MMR status, and PCR
to determine MSI status [20]. Fifteen percent of colorectal cancers are considered mismatch
repair deficient, microsatellite instability-high (dMMR-MSI-H) tumours [19,20]. Whilst
traditional chemotherapy is less effective, these patients have a better prognosis. As a
result of the better prognosis, only around 5% of those with metastatic CRC are dMMR-
MSI-H tumours. In patients that have a mismatch-repair deficient tumour, there is a high
tumour mutational burden (TMB) (more than 12 mutations per 106 DNA bases) which
offers a high number of neoantigens which are recognised as foreign by the local patrolling
immune cells [19,21]. As a result, largely due to an upregulated T cell response with
tumour-infiltrating lymphocytes in these tumours induced by higher neoantigen exposure,
an activated immune response, as well as a target for immune checkpoint inhibition, occurs.
As much as nearly 20% of all colorectal tumours are considered to possess high TMB [22,23].
This demonstrates that high neoantigen expression is seen in some microsatellite stable
tumours, such as those with base excision repair mutations or polymerase proofreading
mutations, including POLE and POLD1 mutations [22].
2.2. Role of Immunotherapy in Serrated Adenocarcinoma of the Colon
Approximately 15–30% of colorectal cancers derive from the serrated pathway in
contrast with the conventional adenoma–carcinoma sequence [24]. BRAF and KRAS
mutant tumours have been shown to have a role in serrated biology [25]. BRAF initiating
mutations can drive an MSI-H phenotype and often co-exists with MUC5AC mutations.
However, the vast majority of serrated adenocarcinomas arise from MSS lesions. This is
comprehensively reviewed elsewhere [26].
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2.3. Consensus Molecular Subtypes in CRC
With the increasing understanding of the heterogeneity of colorectal cancer, the CRC
consensus molecular subtype (CMS) classification has been agreed upon through the study
of patients at multiple centres and whole transcriptomic analysis of tumour tissue [27].
CMS1 (“MSI Immune”), which represents 14% of patients, has high MSI with significant
immune infiltration. Pathways affected include MMR and the PD-1/PD-L1 axis, with
BRAF mutations. The most common subtype seen in 37% is CMS2 (“Canonical”), which,
by contrast, has low MSI, but high somatic copy number alteration (SCNA) with mutations
of P53 with Wnt/Myc signalling pathways affected. CMS3 (“Metabolic”) is only seen in
13% with mixed MSI status, and hypermethylation and metabolic pathways are affected.
KRAS and PIC3CA mutations are observed in this group. Finally, CMS4 (“Mesenchymal”)
subtype occurs in 23% of tumours, with low MSI, high somatic copy number alterations
(SCNA), large stromal infiltration and driven by upregulation of TGF beta pathways,
resulting in epidermal to mesenchymal transformation and extracellular matrix (ECM)
remodelling. The CMS system aims to identify subtypes of CRC to stratify approaches
based on phenotypes. It is worth highlighting that CMS1 and CMS4 have strong immune-
related signatures. Whilst CMS1 is associated with MSI, increased T cell infiltration,
and thus more likely to respond to immune checkpoint inhibitors, CMS4 is particularly
immunosuppressive modulated by TGF beta upregulation. Combination therapy, which
aims to activate and restore T-cell depletion whilst unlocking resistance pathways, may
offer benefits in the setting of CMS4, where patients have the poorest prognosis.
2.4. Transcriptomic Profiling of Metastatic Colorectal Cancer
Further characterisation of not just primary colorectal tumours but also the metastatic
lesion has given further insight into the complex biology of this disease. Pitroda and
colleagues investigated molecular subtypes of colorectal liver metastases by combining
CMS subtyping with mRNA and miRNA expression [28]. They concluded that in the
metastatic setting, molecular features of the primary tumour were less prognostic and
that analysis of the metastatic deposit differed and could more powerfully predict clinical
outcomes based on three groups: canonical, immune and stromal subtypes. Differential
genomic signatures between the primary tumour and the metastatic deposit have been
demonstrated by other groups [29].
We believe that future approaches will weaponise emerging technology to characterise
and define the tumour in patients with metastatic colorectal cancer, and this will guide
initial therapy. Determining how systemic treatment changes the transcriptomic phenotype
will maximise efficacy by adapting the personalised strategy to affect the T-cell response,
as well as macrophage, neutrophil and ECM as collectively important components of the
tumour microenvironment.
3. Colorectal Cancer and the Tumour Microenvironment—An Immunological Basis for
Targeted Therapy
Most solid tumours generate some form of local inflammatory response. Under
histological assessment, the invasion of adenocarcinoma through the muscularis and into
the submucosa is met with immune cells at the invasive edge. On this battleground, resident
and recruited cells aim to control and eliminate cancer cells through direct cytotoxicity,
production of cytokines and through phagocytosis. However, colorectal cancer counters
such mechanisms by the subversion of immune cells through apoptosis, converting cells to
tumour-promoting phenotypes and adopting changes in surrounding stroma, inducing
angiogenesis and ultimately, through migration and invasion. In patients with CMS1,
with dMMR-MSI-H tumours, there is a high concentration of immune cells at the invasive
edge [15]. It is likely that the degree of mutations resulting in high numbers of neoantigens
on the tumoural surface is detected by resident immune cells and generates a robust
immune response with recruitment and activation. As a result, such patients have a better
prognosis [20]. Through the upregulation of PD1/PD-L1 pathways, tumours expressing
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higher levels of PD-L1 seem to have a worse prognosis, presumably through generating the
“brakes” to achieve negative co-stimulation in surrounding immune cells and achieving
immune privilege. By comparison, higher expression of PD-1/PD-L1 in the stromal
immune cells appears to reflect active inflammation and is associated with better outcomes.
3.1. T-Cells
T-cells are traditionally considered part of the adaptive immune system. CD8 cells
differentiate into CTL (cytotoxic T lymphocytes) after engagement with antigen-presenting
cells (APC) to destroy tumour cells through perforin and granzyme granules. CD4 cells,
T-helper-1 cells, support the response through cytokine production, such as IL-2 and IFN
gamma, to promote T-cell maturation and activation of macrophages. Galon and colleagues
showed that increased CD3 and CD8 T-cells at the tumour core and the invasive front,
measurably by the Immunoscore, were associated with better prognosis [30]. Indeed, the
infiltration of T-cells into the tumour itself is termed “tumour-infiltrating” lymphocytes
(TILs) [31]. This observation suggests an activated cellular response and is associated with
survival. However, increased expression of CTLA-4 interacts with CD80 and CD86 on
APCs, preventing a co-stimulatory signal. PD-1 expression engages with PD-L1 on tumour
cells as well as APCs causing a co-inhibitory signal and decreasing APC activation and
promoting T-cell anergy and apoptosis.
T-regulatory (Treg) cells infiltrate the tumour microenvironment, which suppresses
T-cell activation and the antitumoural response. Tregs produce suppressive cytokines, such
as TGF beta, and express checkpoint proteins, such as PD-L1, LAG3 and CTLA4. Whilst
increased numbers of CD3 and CD8 T-cells to the invasive front are associated with better
outcomes in CRC, increased numbers of Tregs are associated with worse outcomes [31].
Additionally, CD4 T cells can differentiate into Th2, Th9, Th17, Th22, as well as T regulatory
cells. Th2 and Th17 promote chronic inflammation, which hampers Th1 functions and
promotes angiogenesis and immunosuppression. Additionally, along with NK cells and
Th17 cells, Th22 cells secrete IL-22, which has a similar structure to IL-10, which promotes
tumour progression. Associated STAT3 activation favours immunosuppressive functions
of other immune cells, including dendritic cells and macrophages [32].
3.2. Natural Killer Cells
Natural Killer (NK) cells are a critical part of the innate immune response, which
function to rapidly cause programmed cell death in cancerous cells lacking MHC I. In-
creased numbers of tumour-infiltrating NK cells, as well as T cells, in the specimens of
resected colorectal liver metastases after neoadjuvant chemotherapy are predictive of
overall survival [33].
3.3. Dendritic Cells
Dendritic cells (DCs) are resident, specialised APCs which coordinate the innate and
adaptive responses. They act to promote tumour rejection through priming effect T-cells
and phagocytose tumour antigens. DCs have been a target for vaccines against tumour
antigens [34].
3.4. Myeloid Cells
Following the extravasation of circulating monocytes, these cells become macrophages.
They are part of the innate response and are the centrepiece to cancer-associated inflam-
mation [35,36]. Activated macrophages which occur through stimulation by IFN gamma,
lipopolysaccharide (LPS) and TNF alpha, are termed M1 macrophages and are considered
to be antitumoural in their role [37]. By comparison, M2 macrophages occur through
exposure to IL-4 or IL-13 and are thought to be more tumourigenic. In later stages, tumour-
associated macrophages (TAMs) tend to polarise towards an M2 phenotype which secrete
IL-10 and TGF beta, promoting immunosuppression, impairing T cells and influencing the
tumour microenvironment (TME) through angiogenesis (such as VEGF) and the extracellu-
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lar matrix (such as through MMP9) [38]. Sites of metastases secrete CCL2 which attracts
circulating monocytes to the metastatic tumour deposit.
Myeloid-derived suppressor cells (MDSCs) represent an immature population of bone
marrow-derived cells which are broadly granulocytic (G-MDSC) or monocytic (M-MDSC).
Following activation, immunosuppressive functions are acquired through upregulation
of Arg1 and inducible nitrox oxide synthase (iNOS, and through CXCL1 from tumour
cells, MDSCs express idoleamine 2,3 dixoygenase (IDO) within the TME promoting T cell
apoptosis, inhibiting T cell function and suppressing T cell infiltration [32]. As a result,
MDSCs are a major player in preventing the effectiveness of immunotherapy.
3.5. Neutrophils
Neutrophils are classically the first immune cell recruited to injury or inflammation.
Tumour-associated neutrophils (TANs) demonstrate a similar phenotype in the early stage
of cancer. These N1 TANs help educate T cells to reject tumours, promote tumour cell
apoptosis through TRAIL and secrete reactive oxygen species (ROS). However, N2 TANs
which are associated with later-stage cancer, driven by TGF beta, can promote angiogenesis,
release MMP8 to degrade the ECM and secrete leukotrienes which expand tumour cells
and worsen survival [32].
3.6. Translating Immunopathology Understanding into Therapeutics
Thus, the effect of colorectal cancer-associated inflammation leads to dysregulation
of multiple signalling pathways and stimulations, a chronic inflammatory process that
influences the local immune cell populations and their function and phenotype. Failed
antitumoural immunity and an immunosuppressive tumour microenvironment lead to the
progress of the primary tumour and create a systemic pre-metastatic niche to promote the
spread to local and distant sites. This is summarised in Figure 1. The changes in function
described in the above section highlight an opportunity to interfere with this sequence of
events, providing a natural role and rationale for immunotherapy.
Cancers 2021, 13, x FOR PEER REVIEW 6 of 18 
 
 
tumour-associated macrophages (TAMs) tend to polarise towards an M2 phenotype 
which secrete IL-10 and TGF beta, promoting immunosuppression, impairing T cells and 
influencing the tumour microenvironment (TME) through angiogenesis (such as VEGF) 
and the extracellular matrix (such as through MMP9) [38]. Sites of metastases secrete 
CCL2 which attracts circulating monocytes to the metastatic tumour deposit. 
Myeloid-derived suppressor cells (MDSCs) represent an immature p pulation of 
bone marrow- erived cells which ar  broadly granulocytic (G-MDSC) or monocytic (M-
MDSC). Following activation, immunosuppressive functions are acquired through upreg-
ulation of Arg1 and inducible nitrox oxide synthase (iNOS, and through CXCL1 from tu-
mour cells, MDSCs express idoleamine 2,3 dixoygenase (IDO) within the TME promoting 
T cell apoptosis, inhibiting T cell function and suppressing T cell infiltration [32]. As a 
result, MDSCs are a major player in preventing the effectiveness of immunotherapy.  
3.5. Neutrophils  
Neutrophils are classically the first immune cell recruited to injury or inflammation. 
Tumour-associated neutrophils (TANs) demonstrate a similar phenotype in the early 
stage of cancer. These N1 TANs help ducate T cells to reject tumours, prom te tumour 
cell poptosis through TRAIL and se rete reactive oxygen species (ROS). However, N2 
TANs which are associat d with later-stage cancer, driven by TGF beta, can romote an-
giogenesis, release MMP8 to degrade the ECM and secrete leukotrienes which expand 
tumour cells and worsen survival [32]. 
3.6. Translating Immunopathology Understanding into Therapeutics 
Thus, the effect of colorectal cancer-associated inflammation leads to dysregulation 
of multiple signalling pathways and stimulations, a chronic inflammatory process that 
influences the local immune cell populations and their function and phenotype. Failed 
antitumoural immunity and an immunosuppressive tumour microenvironment lead to 
the progress of the primary tumour and create a syste ic re-metastatic niche to promote 
the spread to local and dis an  sites. This i  summa  in Figure 1. The changes in fu c-
tion described in the above section highlight an pportunity to int rf re with thi  se-

























Cytokines, chemokines & exosomes from primary 
tumor 
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Figure 1. Cellular interactions in colorectal cancer metastasis. This proposed model illustrates the key changes in immune
cells in an immunosuppressive tumour microenvironment, preventing surveillance, control and elimination of invading
metastatic tumour cells. IDO, indoleamine 2,3-dioxygenase; IL, interleukin; MDSC, myeloid derived suppressor cells;
MMP, matrix metalloproteinase; NO, nitric oxide; PD-1, programmed cell death receptor 1; PD-L1, programmed cell death
receptor ligand 1; Treg, T regulatory cell; TAM, tumour associated macrophage; TAN, tumour-associated neutrophil; TGF,
transforming growth factor; VEGF, vascular endothelial growth factor.
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Immune checkpoint inhibition has been the most successful form of immunotherapy
for solid tumours. There has been strong evidence leading to a new era of therapy in
malignant melanoma and lung cancer with the use of popular immune checkpoint in-
hibitors, which are being applied to colorectal cancer. The most promising results have
been demonstrated in patients with deficient MMR status and MSI-H which is discussed
in the next section. The most common immune checkpoint inhibitors in use and their
molecular target are summarised in Table 1. A summary of prospective trials of immune
checkpoint inhibitors is shown in Table 2 [39–54].
Table 1. Types of immune checkpoint inhibitors.











Table 2. Prospective studies of immune checkpoint inhibitors in metastatic colorectal cancer.
First Author Journal Year Type Target PatientSelection Generic Type Key Findings




CTLA4 All patients Tremelimumab Phase II
Response rate 27% for
nivolumab only, and 15% in
nivolumab plus ipilimumab.










No clear benefit but one
patient with partial
response.










Phase I No objective responses inpatients with CRC.




PD-1 Both dMMRand pMMR Pembrolizumab Phase II
Response rates at 31% by 12
months, with 69% disease
control rate of 3 months or
longer.





PD-L1 All patients Atezolizumab Phase 1b No objective responses inpatients with CRC.











early, were manageable, and
did not affect outcome






L1/MEK All patients Atezolizumab Phase 1b
Response rates were 8% for
anti-PD-L1/bev, compared
with 36% in patients with
anti-PD-L1/bev/FOLFOX6




PD-1 HighMSI/dMMR Pembrolizumab Phase II
Prolonged OS in advanced
refractory CRC.




PD-1 All patients Nivolumab Phase II
Response rates at 55%, with
disease control rates for
more than 3 months in 80%.












Responses in 53% patients,
with complete responses in
21%.











Phase II Response rate 40% in dMMRand 0% in pMMR
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Table 2. Cont.
First Author Journal Year Type Target PatientSelection Generic Type Key Findings






CTLA4 All patients Atezolizumab Phase II
No patients had a tumour
response.






MEK/VEGFR2 All patients Atezolizumab Phase III
No response, disease control
rate in 78%, progression in
22%.



















Phase II No major safety concerns.Ongoing enrolment.





PD-1 MSS Nivolumab Phase II
Overall response rate 17%,
not
associated PD-L1 expression.





VEGFR2 MSS/pMMR Mixture Retrospective Response rate 8%.




PD-1 MSI-H/dMMR Pembrolizumab Phase III



















response rates from 4 to 8%.
4. MMR Deficient—MSI-High Metastatic Colorectal Cancer
Immune checkpoint inhibition to target metastatic colorectal cancer was investigated
by Le et al. in the Keynote-016 study. This phase I study of chemorefractory patients
included those with both deficient and proficient MMR status who were treated with
pembrolizumab [44]. In patients with deficient MMR status, this PD-1 inhibitor led to
radiographic response rates in 33%, with up to 21% having a complete response rate. A
follow-up report demonstrated a response rate of 40% in MMR deficient patients, at a 53%
rate of progression-free survival (PFS) [41].
Further PD-1 inhibition using nivolumab was utilised in the Checkmate-142 study.
Anti-PD-1 monotherapy was used in 74 patients with deficient MMR status [43]. An
objective response was found in 31% of patients, with 69% of patients exhibiting disease
control by a median follow-up of 12 months. Interestingly, immunohistochemistry of
tumoural PD-L1 expression, KRAS and BRAF status were not predictive of response to
immunotherapy. The most common side effect was fatigue and diarrhoea (in 22% of
patients each), and less frequently hypothyroidism, hepatitis, arthralgia and pancreatitis.
A further cohort of the Checkmate-142 study investigated 119 patients undergoing
combination therapy with anti-PD-1 and anti-CTLA-4 immunotherapy (nivolumab and
ipilimumab, respectively). In this group of MMR deficient patients, response rates of 55%
with disease control rates (DCR) of 80% were observed. Progression-free survival of 71% at
1 year was achieved, with overall survival (OS) at 85% at 1 year. The combination was more
effective compared with nivolumab monotherapy (overall response rate of 55% compared
with 31). However, 32% of patients experienced grade 3 or grade 4 side effects [42].
Further evidence for checkpoint inhibition in MMR deficient, microsatellite instability
(MSI)-high patients was reported in the Keynote-164 study in 2020 [57]. One hundred
twenty-four patients who had at least one previous line of therapy were recruited to this
phase II study, 33% of which demonstrated a positive response to pembrolizumab. The
first cohort of patients had >2 prior therapies and experienced a mean PFS of 2.3 months
and median OS of 31.4 months. The second cohort, who only had >1 previous therapy, had
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a median PFS of 4.1 months and median OS, which was not reached by the time of analysis.
Grade 3 or 4 side effects were seen in 16% and 13% of cohort A and B patients, respectively.
The Keynote-177 study was recently published in NEJM [21]. This phase III study
included 307 MMR deficient–MSI-high patients who were treatment naïve. Pembrolizumab
was compared with traditional chemotherapy (5FU with or without bevacizumab or cetux-
imab). Pembrolizumab was superior to chemotherapy with PFS of 16.6 months compared
with 8.2 months, and the median OS has not yet been reached in the pembrolizumab group
but was 36.7 months in the chemotherapy group based on the recent update [58]. An
overall response rate was 43.8% in the pembrolizumab group, compared with 33.1% in
the chemotherapy group. Importantly, only 22% of patients experienced grade 3 or 4 side
effects in the pembrolizumab, compared with 66% in the chemotherapy group. Improved
quality of life was also reported in the pembrolizumab monotherapy group in a follow-up
report [59].
A Canadian study recently reported in JAMA Oncology investigated combination
immunotherapy with tremelimumab and durvalumab compared with best supportive care
in patients with metastatic refractory CRC [40]. In this phase II study (which included
unselected patients based on MSI status), 180 patients were enrolled and found a median
OS of 6.6 months in the immunotherapy group compared to 4.1 months in the supportive
care group. A meagre improvement in PFS was seen with 1.8 months with immunotherapy
compared with 1.9 months in the supportive care group. Up to 64% of patients experienced
at least one grade 3 side effect related to immunotherapy. The authors concluded that
OS was improved even in microsatellite stable metastatic CRC. Plasma measurements of
tumour mutational burden (TMB) highlighted that increased TMB levels were associated
with improved efficacy.
Thus, there is a rationale for upfront PD1 directed immunotherapy in MMR deficient
patients. However, late-stage patients who are refractory to other chemotherapies fail
to benefit.
5. MSS Metastatic Colorectal Cancer
The efficacy of immune checkpoint inhibitors has been far less successful in microsatel-
lite stable (MSS) colorectal cancers. The Keynote-016 study discussed in the earlier section
had included 18 patients with chemorefractory metastatic colorectal cancer and profi-
cient MMR status were treated with pembrolizumab and found no responses in these
patients [44].
Shahda and colleagues presented preliminary results of a phase II study combining
pembrolizumab alongside chemotherapy (mFOLFOX6) irrespective of MMR status [60].
They found that of 30 patients enrolled, a complete response was seen in 1 patient, a partial
response in 15 patients and 14 patients demonstrated stable disease. This is an ongoing
study that was promising for MMR proficient patients.
Due to the poor results seen in immune checkpoint inhibition, this has led to a
number of studies using various combination strategies aiming to improve the efficacy
of immunotherapy in MMR proficient metastatic colorectal cancer [61]. Combination
strategies will be discussed in the following section.
6. Combination Strategies in Metastatic Colorectal Cancer—Overcoming Resistance
In patients with microsatellite instable-MMR deficient metastatic colorectal cancer,
the high tumour mutational burden with high neoantigen rates creates increased MHC I
expression and increased numbers of infiltrating CD8 T-cells. The concept of combining
immunotherapy with an additional modality attempts to synergistically stimulate the
tumour microenvironment to increase interferon-gamma and other cytokines and promote
immune cell recruitment.
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6.1. Immunotherapy and MEK Inhibitors
In order to assess the role of atezolizumab alongside traditional chemotherapy, the
MODUL trial used a biomarker-driven approach [62]. Following standard induction across
groups with FOLFOX and bevacizumab, depending on the status of BRAF, MSI and HER2,
different regimes were trialled compared with 5FU or capecitabine with bevacizumab.
Atezolizumab was used alongside patents a fluoropyrimidine/bevacizumab if MSI high
was identified, or alongside cobimetanib in one of the umbrella cohorts. In BRAF wild-type
patients, the use of bevacizumab is hoped to increase T cell trafficking whilst reducing
Treg/MDSC infiltration and thus improve immune checkpoint efficacy. Similarly, the
combination with a MEK inhibitor aims to sensitise tumours to atezolizumab. Final results
are eagerly awaited.
A MEK inhibitor (cobimetanib) was used in combination with atezolizumab in the
IMblaze 370 trial [54]. This included 363 patients with unresectable or metastatic colorectal
cancer and compared the combination of MEK inhibitor and PD-L1 inhibitor against PD-L1
inhibitor alone or regorafenib (EGFR/VEGF inhibitor). Patients had microsatellite stable
disease in 93%, 92% and 89% in each group, respectively. The authors reported that median
overall survival was 8.87 months using the combination, compared with 2.1 months with
atezolizumab and 8.51 months with regorafenib. The lack of benefit using immunotherapy,
with or without the combination of a MEK inhibitor, reinforced the poor responses of
immunotherapy in patients with low levels of inflammation.
The combination of cobimetanib and atezolizumab was reported by Bendell and
colleagues in a phase 1b trial in 2016 [63]. This suggested responses in some MSS colorectal
cancer irrespective of PD-L1 expression, with responders showing upregulated PD-L1
expression and T-cell infiltration. Subsequently, Hellmann and colleagues reported a
response rate in seven patients (8%) of the cohort, of whom six patients had microsatellite
stable status [64].
6.2. Immunotherapy and CEA Inhibition
Targeting carcinogenic embryonic antigen on tumour cells and CD3 T cells is under
investigation which aims to promote T cell infiltration and upregulate PD-L1 [65]. A phase
I dose-escalation study compares this agent as monotherapy against a combination of CEA
(carcinoembryonic antigen) antibody and atezolizumab in both MSS and MSI patients.
The authors report that at high doses, many patients demonstrated tumour inflammation
and a partial response seen in 5% of patients receiving monotherapy and 20% of those
receiving the combination with immune checkpoint inhibition. Interestingly, all patients
had tumours which were microsatellite stable.
6.3. Immunotherapy and IDO Inhibitors
The immunosuppressive enzyme idoleamine 2,3-dioxygenase (IDO) has been a target
of inhibition in combination with nivolumab in the ECHO-204 study [66]. This included
241 patients with various advanced solid cancers and was performed as a phase 1/2 dose-
escalation study. In the 25 colorectal cancer patients, overall response rates were 4% and
disease control rates of 24%.
6.4. Immunotherapy and Radiotherapy
As immune checkpoint inhibitors have low efficacy alone in patients with proficient
MMR metastatic colorectal cancer, investigators are studying the potential combination
of radiotherapy (RT) and immunotherapy. Segal and colleagues studied 26 patients with
unresectable or recurrent metastatic colorectal cancer who have already failed at least
two standard therapies [67]. They received palliative RT or ablation to the lesion (this
varied between colorectum, liver, lung or bone) along with pembrolizumab. Interim
overall response rates were 9% in patients receiving radiotherapy, with no responses in the
ablation group. The hypothesis by combining radiotherapy with immunotherapy is that
irradiation will induce a local inflammatory response and thus upregulation of PD1/PD-L1
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pathways, which will improve the efficacy of immune checkpoint inhibition. This is under
investigation in the PRIME-RT trial in patients with locally advanced rectal cancer, which
includes patients with both proficient and deficient MMR status undergoing durvalumab
alongside extended neoadjuvant regimes (NCT04621370).
The Checkmate-142 study, which was discussed earlier in this review, also included
additional treatment arms utilising combinations of immunotherapy. This included
nivolumab and anti-LAG3 antibodies (another co-inhibitory protein), and combination
with nivolumab, ipilimumab and cobimetanib (MEK inhibitor) and nivolumab with dara-
tumumab (anti-CD38 antibody)—a protein previously associated with tumour cells of
myeloma.
7. Preclinical Studies Investigating Promising Immunotherapy Strategies in
Metastatic Colorectal Cancer
New targets for therapy continue to be identified via ongoing translational research to
identify underpinning molecular mechanisms of immunopathology. Macrophages within
the tumour microenvironment have been identified as key players in tumour progression,
where an M2 phenotype creates resistance to anti-PD-1/PD-L1 agents [38]. In preclinical
models, CSF1 receptor blockade has been effective in polarisation to M1 macrophages and
restoring effective immune checkpoint immunotherapy. This is now under investigation in
both pancreatic and colorectal cancer using a combination of durvalumab and pexidartinib
(anti-CSF1R) (NCT02777710).
Other emerging therapies include antibodies targeting OX40 and CD73 immunother-
apy. OX40 (CD134) is a member of the TNF receptor superfamily with a role in co-
stimulatory immune responses, which are expressed on T-cells. This interacts with OX40
ligand on antigen-presenting cells resulting in activation of NFKB and NFAT. Given the
high levels expressed on Tregs and increases in the generation of those and similar im-
munosuppressive T cell subsets, OX40 inhibition aims to counteract tumour-infiltrating
Tregs and thus aims to improve immune checkpoint efficacy [68]. CD73 is a novel immune
checkpoint protein associated with tumour progression and suppressing antitumoural
immune responses. Combination with CD73 monoclonal antibodies and immune check-
point inhibitors is under clinical investigation for solid organ tumours [69]. There are many
more examples of novel targets relating to immunotherapy that are beyond the scope of
this review.
8. Genomic Biomarkers of Response to Immunotherapy
A difficulty remains in defining which patients will respond best to immunotherapy.
Consistently across different tumour types, tumour mutational burden is a strong predictor,
particularly in melanoma and non-small cell lung cancer [70]. The more somatic mutations
a tumour has, the more likely it is to present neoantigens. However, it is dependent
on the mutation whether a peptide is loaded onto the MHC and presented to T cells,
with only a minority being presented in this fashion [71]. Amongst colorectal cancer,
mutational burden has proven to be an excellent predictor of response to ICB in MSI-H
patients [72], whilst it is acknowledged that certain MSS patients have a high mutational
burden, but these numbers, when studied, are in the order of 164/5704 [73]. However,
Alexandrov et al. took this further by examining the influence of “characteristic mutational
processes” on cancer. Through detailed examination of somatic mutations obtained from
registered genome sequences, the authors demonstrated the ability to derive multiple
new single base substitution signatures, small insertions and deletions and double base
signatures [74]. These data will, in the future, yield information on how these processes
lead to carcinogenesis and are processed by the immune system. Indeed, for example, the
identification of the APOBEC mutational signature has shown some promise in NSCLC in
combination with mutational burden in identifying patients that respond better to ICB [75].
Patients demonstrated higher levels of effector immune cell infiltration to their tumours
and reduction in regulatory T cells. Patterns of mutations in MSS CRC may include novel
DNA damage mutations, including ATM, which can sensitise patients to durable responses
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to ICB [76]. Increasingly advanced techniques of pattern recognition are being explored in
this field with advances in digital pathology. MSI status, though now universally tested, can
be predicted using deep learning algorithms and artificial intelligence from histology [77].
Additionally, common actionable mutations can be detected in a similar fashion, and this
technology holds hope for the development of personalised treatment algorithms [78].
9. Strategies to Improve Outcomes
Many basic science and clinical researchers are exploring different avenues in order
to make stepwise gains in the advancement of care for patients with metastatic colorectal
cancer. New technologies allow for better characterisation of the genomic and molecular
mechanisms underpinning colorectal cancer and the pathological responses of the local and
systemic immune components. More realistic preclinical models using autochthonous mod-
els, organoids and patient-derived xenografts in animals permit the study of novel agents
which target not just inflammatory pathways but also have potential to reprogramme
pro-tumourigenic pathways regulated by cancer-associated lymphocytes, macrophages,
neutrophils and cancer-associated fibroblasts.
Tauriello and colleagues adopted a model of murine metastatic colorectal cancer
with APC, p53, KRAS and TGF-β mutations [79]. This produced a microsatellite-stable
phenotype that had limited responses to PD-1/PD-L1 inhibition but revealed a TGFβ-
driven suppression of T-cells and specifically TH1 cells. Jackstadt et al. further established
using an autochthonous model of serrated adenocarcinoma that TGFβ signalling drove
neutrophilic infiltration to spontaneous liver metastases, a phenotype that was inhibited
through neutrophil and TGFβ inhibition [80]. Given the reproducible nature of patient-
derived organoids and patient-derived xenografts and their representative therapeutic
responses in patients, they have the power to become a tool to investigate novel im-
munotherapeutics for patients with metastatic colorectal cancer. Engraftment of colorectal
cancer to immunocompetent mice using genetically engineered mice organoids, wild-type
organoids or patient-derived human CRC organoids can be used to study in vivo immuno-
logical interactions in the setting of metastatic colorectal cancer [81]. In a world with
increasing challenges in clinical academia due to the coronavirus pandemic, supporting
the discovery and translation of new approaches in armouring and modifying the immune
response is critical. One example of this is the Accelerator Award from CRUK, which
aims to support infrastructures, such as sharing datasets, models and tissue biobanks
and support facets of oncology research, such as preclinical studies, biomarkers, imaging,
radiotherapy and engineering approaches [82]. Immunotherapies other than immune
checkpoint inhibitors, which have been studied, were identified in our literature search
and are summarised in Supplementary Table S1.
The influence of gut microbiota on the tumour microenvironment and, therefore,
responses to immunotherapy are wide-ranging, varied, and yet to be fully explored. The
microbiome in the gut is predominated by anaerobes, different species of whom have
been shown to have influences on different immune cells within tumours, in addition to
interacting directly with immune checkpoints. These interactions are thoroughly described
in previous review material [83]. Personalised responses to ICB (immune checkpoint block-
ade) are a result of this heterogeneity influenced by gut flora. Whilst enterococcus faecium
and klebsiella pneumonia are common gut pathogens associated with positive responses to
ICB, patients with high numbers of lactobacillus have poorer responses. It is increasingly
likely as trials develop, particularly in MSS colorectal cancer, that microbial species in
faeces may be first studied to help predict responses and altered to enhance efficacy.
Patients with metastatic colorectal disease range from those with low burden oligome
tastatic hepatic disease to overwhelming, aggressive widespread metastases. Given the
range of colorectal cancer subtypes based on the location of primary and CMS phenotypes,
then it is likely that it will take different strategies to improve survival for stratified
patient groups (Figure 2). For example, using immunotherapy as an adjunct in the pre- or
post-operative phases, will benefit patients with potentially curative metastatic colorectal
Cancers 2021, 13, 3566 13 of 17
cancer, which is very different from identifying molecular subtypes amenable to new
immunotherapies to achieve better palliation or partial responses in certain subsets of
widespread metastatic disease in patients that present with palliative disease.
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factor 1 receptor; IDO, indoleamine 2,3-dioxygenase; TGF, transforming growth factor; CAR-T, chimeric antigen receptor
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10. Conclusions
Metastatic colorectal cancer cont nu s to hav a dismal prognosis and is a major cause
of death in the Western world. Established regimes for chemotherapy have r latively poor
rat s of response yet cause significant side effects whic im air quality of life in e d-stage
disease. Immunotherapy r present a n w dawn of ther peutics, which could not only
improve the balance of benefit and side effect profile but also may offer better responses in
certain patient groups. We have discussed the goals of the clinical and scientific community
in discovering how to translate the benefits and efficacy of immune checkpoint inhibitors
and other novel agents to the right groups of patients.
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